ClinicalTrials.gg
CompletedNCT02867813FOURIER OLEUpdated Apr 7, 2023Results posted

Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk Open-label Extension

A Phase 3 interventional study of Evolocumab in Dyslipidemia, sponsored by Amgen. Completed at 198 sites in 7 countries. Open to participants aged 40 Years to 85 Years. Per ClinicalTrials.gov, last updated 2023-04-07.

Sponsored by Amgen · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
5,035
Allocation
Not applicable
Ages
40 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing evolocumab in Dyslipidemias — none open to participants now, none under way, none of them phase 3. evolocumab · Dyslipidemias.

Enrollment
2nd of 10
5,035 · median 409
Started
2016
with 1 other
Phase 3
7 of 10
none open now
Registered
6th of 10
by date
Lead sponsor
7 of 10
Amgen

Among the 10 studies testing evolocumab in Dyslipidemias, this one is the 2nd largest by enrollment, is one of 2 that started in 2016, is one of 7 in phase 3, and was the 6th registered.

Dyslipidemias

1,249 studies on the registry are indexed under Dyslipidemias; 177 are open to participants now.

Browse Dyslipidemias studies →

Open to participants now

None of the 10 studies testing evolocumab in Dyslipidemias is open now. The open studies under Dyslipidemias, anywhere →

About evolocumab

evolocumab: first FDA approval 2015 (REPATHA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 112 Dyslipidemias studies recruiting now, 55 (49%) set no upper age limit and 36 (32%) stop at 75 or younger; 11 take children under 18; 29 take healthy volunteers.

This study: 40 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies testing evolocumab in Dyslipidemias as a file.
02

Study summary

The primary clinical hypothesis is that long-term exposure of evolocumab will be safe and well tolerated in subjects with clinically evident atherosclerotic cardiovascular disease (CVD).

Read the detailed description

This is a multicenter, open-label extension study designed to assess the long-term safety of evolocumab in subjects who completed the FOURIER study,which is a randomized placebo-controlled study of evolocumab in subjects with clinically evident atherosclerotic CVD on stable effective statin therapy. Eligible subjects at sites participating in FOURIER OLE who have signed the FOURIER OLE informed consent may be enrolled at the completion of FOURIER study.

03

Conditions studied

  • Dyslipidemia

Keywords

  • High Cholesterol
  • Treatment for high cholesterol
  • Lowering cholesterol
  • Lowering high cholesterol
  • Hypercholesterolemia
04

Who can participate

Ages eligible
40 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject has provided before initiation of any study-specific activities/procedures
  • Subject has completed FOURIER (Study 20110118) while still receiving assigned product.

Exclusion criteria

Exclusion Criteria:

  • product was permanently discontinued during FOURIER for any reason, including an adverse event or serious adverse event
  • Subject is currently receiving treatment in another investigational device or drug study, or ended treatment on another investigational device or drug study(ies) within less than 4 weeks. Other investigational procedures while participating in this study are excluded
  • Subject is not likely to be available to complete protocol-required study visits or procedures and/or to comply with required study procedures to the best of the subject's and investigator's knowledge
  • Subject has a history or evidence of any other disorder, condition, or disease that, in the opinion of the investigator or Amgen physician, if consulted, would pose a risk to subject safety or interfere with the study evaluation, procedures, or completion
  • Subject has a known sensitivity to any of the active substances or (eg, sodium acetate) to be administered during dosing
  • Female subject is pregnant or breastfeeding or is planning to become pregnant or planning to breastfeed during treatment with evolocumab and within 15 weeks after the end of treatment with evolocumab
  • Female subjects of who are not willing to use an acceptable method(s) of effective during treatment with evolocumab and for an additional 15 weeks after the end of treatment with evolocumab are excluded
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
5,035 participants (actual)

Study arms

  • Experimental
    evolocumab (AMG 145)

    All subjects are randomized to a single arm and will receive evolocumab 140mg every two weeks (Q2W) or 420mg monthly (QM) according to subject's preference.

    Biological: Evolocumab

Interventions

  • BiologicalEvolocumab

    subjects will receive evolocumab 140 mg every 2 weeks (Q2W) or 420 mg monthly (QM), according to the subject's preference.

06

What researchers measure

Primary outcomes

  1. Number of Participants Who Experienced an Adverse Event

    All adverse event summaries for the primary analysis of the primary endpoint (OLE study period only) included all treatment-emergent events reported on the Event electronic case report form (eCRF), including CEC positively reviewed events and disease-related events.

    Time frame: Up to 5 years

Secondary outcomes

  1. Percent Change of Low-density Lipoprotein Cholesterol (LDL-C) From Baseline at Each Scheduled Visit

    Time frame: Week 12, Week 24, Week 48, Week 72, Week 96, Week 120, Week 144, Week 168, Week 192, Week 216, Week 260

  2. Percentage of Participants Who Achieved an LDL-C Level < 40 mg/dL

    Time frame: Week 12, Week 24, Week 48, Week 72, Week 96, Week 120, Week 144, Week 168, Week 192, Week 216, Week 260

07

Results

Posted Feb 28, 2023

Participant flow

This was an open-label extension of study 20110118 (NCT01764633). Eligible participants were enrolled after the completion of the 20110118 study. 5035 participants were enrolled at 195 centers in Czech Republic, Hungary, Poland, Russia, Slovakia, Ukraine, and the United States from 02 September 2016 to 17 March 2022.

Participant flow — Overall Study
MilestonePlacebo Once Every 2 Weeks (Q2W) or Once a Month (QM) in Parent StudyEvolocumab Once Every 2 Weeks (Q2W) or Once a Month (QM) in Parent Study
Started25352500
Completed20842090
Not completed451410
Withdrew: Withdrawal by subject5756
Withdrew: Decision by sponsor77
Withdrew: Lost to follow-up9178
Withdrew: Missing21
Withdrew: Death294268

Outcome measures

PrimaryNumber of Participants Who Experienced an Adverse Event

All adverse event summaries for the primary analysis of the primary endpoint (OLE study period only) included all treatment-emergent events reported on the Event electronic case report form (eCRF), including CEC positively reviewed events and disease-related events.

Time frame:
Up to 5 years
Reported as:
Count of participants · Participants
Number of Participants Who Experienced an Adverse Event
ParticipantsPlacebo Once Every 2 Weeks (Q2W) or Once a Month (QM) in Parent StudyEvolocumab Once Every 2 Weeks (Q2W) or Once a Month (QM) in Parent Study
Number of Participants Who Experienced an Adverse Event21442084
SecondaryPercent Change of Low-density Lipoprotein Cholesterol (LDL-C) From Baseline at Each Scheduled Visit
Time frame:
Week 12, Week 24, Week 48, Week 72, Week 96, Week 120, Week 144, Week 168, Week 192, Week 216, Week 260
Reported as:
Mean · Percent Change
Percent Change of Low-density Lipoprotein Cholesterol (LDL-C) From Baseline at Each Scheduled Visit
Percent ChangePlacebo Once Every 2 Weeks (Q2W) or Once a Month (QM) in Parent StudyEvolocumab Once Every 2 Weeks (Q2W) or Once a Month (QM) in Parent Study
Week 12-55.93 ± 33.73-58.43 ± 30.64
Week 24-56.69 ± 33.58-58.38 ± 31.52
Week 48-58.52 ± 33.66-59.05 ± 33.06
Week 72-56.35 ± 33.73-56.90 ± 33.14
Week 96-55.70 ± 33.72-56.62 ± 33.36
Week 120-53.37 ± 36.77-54.89 ± 35.99
Week 144-56.96 ± 32.82-57.38 ± 32.34
Week 168-56.49 ± 37.04-58.22 ± 34.60
Week 192-57.42 ± 35.43-58.81 ± 33.27
Week 216-54.68 ± 35.53-57.11 ± 32.89
Week 260-53.69 ± 37.51-56.63 ± 36.14
SecondaryPercentage of Participants Who Achieved an LDL-C Level < 40 mg/dL
Time frame:
Week 12, Week 24, Week 48, Week 72, Week 96, Week 120, Week 144, Week 168, Week 192, Week 216, Week 260
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Achieved an LDL-C Level < 40 mg/dL
Percentage of ParticipantsPlacebo Once Every 2 Weeks (Q2W) or Once a Month (QM) in Parent StudyEvolocumab Once Every 2 Weeks (Q2W) or Once a Month (QM) in Parent Study
Week 1258.7 (56.7 to 60.6)61.4 (59.4 to 63.3)
Week 2460.2 (58.2 to 62.1)61.6 (59.7 to 63.5)
Week 4861.7 (59.8 to 63.7)61.9 (60.0 to 63.9)
Week 7259.7 (57.7 to 61.7)58.5 (56.5 to 60.5)
Week 9657.3 (55.3 to 59.3)59.9 (57.8 to 61.9)
Week 12054.6 (52.5 to 56.6)56.4 (54.4 to 58.5)
Week 14459.6 (57.6 to 61.7)60.4 (58.3 to 62.4)
Week 16860.9 (58.8 to 63.0)61.5 (59.4 to 63.5)
Week 19261.8 (59.4 to 64.1)62.3 (59.9 to 64.7)
Week 21656.0 (53.6 to 58.3)59.2 (56.9 to 61.5)
Week 26056.9 (54.6 to 59.1)59.2 (56.9 to 61.4)

Adverse events

Collected over Day 1 up to approximately 5 years during the OLE study.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo in Parent Study309/2,535 (12.2%)1,077/2,532 (42.5%)956/2,532 (37.8%)
Evolocumab in Parent Study287/2,500 (11.5%)1,045/2,499 (41.8%)959/2,499 (38.4%)
Most frequent serious events
Showing 10 of 963
Most frequent serious events
EventPlacebo in Parent StudyEvolocumab in Parent Study
PneumoniaInfections and infestations50/253274/2499
Acute myocardial infarctionCardiac disorders74/253252/2499
Atrial fibrillationCardiac disorders57/253247/2499
Angina pectorisCardiac disorders56/253252/2499
Angina unstableCardiac disorders49/253237/2499
Cardiac failureCardiac disorders46/253244/2499
Coronary artery diseaseCardiac disorders41/253230/2499
Cardiac failure congestiveCardiac disorders37/253240/2499
Non-cardiac chest painGeneral disorders26/253237/2499
OsteoarthritisMusculoskeletal and connective tissue disorders37/253236/2499
Most frequent other events
Most frequent other events
EventPlacebo in Parent StudyEvolocumab in Parent Study
HypertensionVascular disorders327/2532355/2499
Upper respiratory tract infectionInfections and infestations208/2532162/2499
BronchitisInfections and infestations162/2532173/2499
NasopharyngitisInfections and infestations157/2532156/2499
ArthralgiaMusculoskeletal and connective tissue disorders144/2532138/2499
Diabetes mellitusMetabolism and nutrition disorders139/2532135/2499
Back painMusculoskeletal and connective tissue disorders133/2532137/2499

Baseline characteristics

The Overall Number of Baseline Participants is made up of all of the participants that received study drug.

Age, Continuous
Age, Continuous(Years)Placebo Once Every 2 Weeks (Q2W) or Once a Month (QM) in Parent StudyEvolocumab Once Every 2 Weeks (Q2W) or Once a Month (QM) in Parent StudyTotal
Mean62.3 ± 8.462.4 ± 8.562.3 ± 8.4
Sex: Female, Male
Sex: Female, Male(Participants)Placebo Once Every 2 Weeks (Q2W) or Once a Month (QM) in Parent StudyEvolocumab Once Every 2 Weeks (Q2W) or Once a Month (QM) in Parent StudyTotal
Female6386221260
Male189418773771
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Placebo Once Every 2 Weeks (Q2W) or Once a Month (QM) in Parent StudyEvolocumab Once Every 2 Weeks (Q2W) or Once a Month (QM) in Parent StudyTotal
Hispanic or Latino5563118
Not Hispanic or Latino247724364913
Unknown or Not Reported000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Placebo Once Every 2 Weeks (Q2W) or Once a Month (QM) in Parent StudyEvolocumab Once Every 2 Weeks (Q2W) or Once a Month (QM) in Parent StudyTotal
American Indian or Alaska Native527
Asian92130
Black or African American111117228
Native Hawaiian or Other Pacific Islander549
White239223454737
Multiple448
Other6612
08

Study locations

198 sites
  • Research Site
    Birmingham, Alabama 35294, United States
  • Research Site
    Huntsville, Alabama 35801, United States
  • Research Site
    Phoenix, Arizona 85018, United States
  • Research Site
    Banning, California 92220, United States
  • Research Site
    Long Beach, California 90807, United States
  • Research Site
    Oceanside, California 92056, United States
  • Research Site
    Oxnard, California 93030, United States
  • Research Site
    Palm Springs, California 92262, United States
  • Research Site
    Roseville, California 95661, United States
  • Research Site
    San Diego, California 92161, United States
  • Research Site
    San Pedro, California 90732, United States
  • Research Site
    Tarzana, California 91356, United States
  • Research Site
    Torrance, California 90502, United States
  • Research Site
    Valley Village, California 91607, United States
  • Research Site
    Aurora, Colorado 80012, United States
  • Research Site
    Colorado Springs, Colorado 80909, United States
  • Research Site
    Denver, Colorado 80218, United States
  • Research Site
    Littleton, Colorado 80120, United States
  • Research Site
    Boynton Beach, Florida 33472, United States
  • Research Site
    Clearwater, Florida 33756, United States
  • Research Site
    Crystal River, Florida 34429, United States
  • Research Site
    Daytona Beach, Florida 32117, United States
  • Research Site
    Hollywood, Florida 33021, United States
  • Research Site
    Hollywood, Florida 33024, United States
  • Research Site
    Jacksonville, Florida 32216, United States
  • Research Site
    Largo, Florida 33777, United States
  • Research Site
    Miami, Florida 33173, United States
  • Research Site
    New Port Richey, Florida 34653, United States
  • Research Site
    Pensacola, Florida 32501, United States
  • Research Site
    Ponte Vedra Beach, Florida 32081, United States
  • Research Site
    Port Charlotte, Florida 33952, United States
  • Research Site
    Saint Petersburg, Florida 33713, United States
  • Research Site
    Sarasota, Florida 34232, United States
  • Research Site
    Sarasota, Florida 34239, United States
  • Research Site
    Athens, Georgia 30606, United States
  • Research Site
    Atlanta, Georgia 30342, United States
  • Research Site
    Augusta, Georgia 30909, United States
  • Research Site
    Dunwoody, Georgia 30338, United States
  • Research Site
    Gainesville, Georgia 30501, United States
  • Research Site
    Savannah, Georgia 31406, United States
  • Research Site
    Suwanee, Georgia 30024, United States
  • Research Site
    Coeur d'Alene, Idaho 83814, United States
  • Research Site
    Meridian, Idaho 83642, United States
  • Research Site
    Addison, Illinois 60101, United States
  • Research Site
    Belleville, Illinois 62220, United States
  • Research Site
    Chicago, Illinois 60616, United States
  • Research Site
    Jerseyville, Illinois 62052, United States
  • Research Site
    Evansville, Indiana 47714, United States
  • Research Site
    Munster, Indiana 46321, United States
  • Research Site
    Iowa City, Iowa 52242, United States
  • Research Site
    Waterloo, Iowa 50702, United States
  • Research Site
    Kansas City, Kansas 66160, United States
  • Research Site
    Wichita, Kansas 67203, United States
  • Research Site
    Lexington, Kentucky 40503, United States
  • Research Site
    Hammond, Louisiana 70403, United States
  • Research Site
    Metairie, Louisiana 70006, United States
  • Research Site
    Monroe, Louisiana 71201, United States
  • Research Site
    Natchitoches, Louisiana 71457, United States
  • Research Site
    Slidell, Louisiana 70458, United States
  • Research Site
    Auburn, Maine 04210, United States
  • Research Site
    Bangor, Maine 04401, United States
  • Research Site
    Biddeford, Maine 04005, United States
  • Research Site
    Baltimore, Maryland 21204, United States
  • Research Site
    Columbia, Maryland 21044, United States
  • Research Site
    Salisbury, Maryland 21804, United States
  • Research Site
    Haverhill, Massachusetts 01830, United States
  • Research Site
    Newton, Massachusetts 02459, United States
  • Research Site
    Grandville, Michigan 49418, United States
  • Research Site
    Lansing, Michigan 48912, United States
  • Research Site
    Muskegon, Michigan 49444, United States
  • Research Site
    Saginaw, Michigan 48601, United States
  • Research Site
    Saint Cloud, Minnesota 56303, United States
  • Research Site
    Saint Paul, Minnesota 55102, United States
  • Research Site
    Tupelo, Mississippi 38801, United States
  • Research Site
    Kansas City, Missouri 64128, United States
  • Research Site
    Saint Louis, Missouri 63128, United States
  • Research Site
    Kalispell, Montana 59901, United States
  • Research Site
    Lincoln, Nebraska 68506, United States
  • Research Site
    Las Vegas, Nevada 89148, United States
  • Research Site
    Voorhees, New Jersey 08043, United States
  • Research Site
    Brooklyn, New York 11206, United States
  • Research Site
    Cortlandt Manor, New York 10567, United States
  • Research Site
    New Hyde Park, New York 11042, United States
  • Research Site
    New Windsor, New York 12553, United States
  • Research Site
    New York, New York 10029, United States
  • Research Site
    Rochester, New York 14609, United States
  • Research Site
    West Seneca, New York 14224, United States
  • Research Site
    Williamsville, New York 14221, United States
  • Research Site
    Calabash, North Carolina 28467, United States
  • Research Site
    Charlotte, North Carolina 28204, United States
  • Research Site
    Greensboro, North Carolina 27408, United States
  • Research Site
    Hickory, North Carolina 28601, United States
  • Research Site
    High Point, North Carolina 27262, United States
  • Research Site
    Mooresville, North Carolina 28117, United States
  • Research Site
    Statesville, North Carolina 28625, United States
  • Research Site
    Tabor City, North Carolina 28463, United States
  • Research Site
    Wilmington, North Carolina 28401, United States
  • Research Site
    Winston-Salem, North Carolina 27103, United States
  • Research Site
    Fargo, North Dakota 58122, United States
  • Research Site
    Canton, Ohio 44710, United States

Showing the first 100 of 198 sites across 7 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • O'Donoghue ML, Giugliano RP, Wiviott SD, Atar D, Keech A, Kuder JF, Im K, Murphy SA, Flores-Arredondo JH, Lopez JAG, Elliott-Davey M, Wang B, Monsalvo ML, Abbasi S, Sabatine MS. Long-Term Evolocumab in Patients With Established Atherosclerotic Cardiovascular Disease. Circulation. 2022 Oct 11;146(15):1109-1119. doi: 10.1161/CIRCULATIONAHA.122.061620. Epub 2022 Aug 29. PubMed 36031810 ↗
  • Gaba P, O'Donoghue ML, Park JG, Wiviott SD, Atar D, Kuder JF, Im K, Murphy SA, De Ferrari GM, Gaciong ZA, Toth K, Gouni-Berthold I, Lopez-Miranda J, Schiele F, Mach F, Flores-Arredondo JH, Lopez JAG, Elliott-Davey M, Wang B, Monsalvo ML, Abbasi S, Giugliano RP, Sabatine MS. Association Between Achieved Low-Density Lipoprotein Cholesterol Levels and Long-Term Cardiovascular and Safety Outcomes: An Analysis of FOURIER-OLE. Circulation. 2023 Apr 18;147(16):1192-1203. doi: 10.1161/CIRCULATIONAHA.122.063399. Epub 2023 Feb 13. PubMed 36779348 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication (or other new use) have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.

Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors, and if not approved, may be further arbitrated by a Data Sharing Independent Review Panel. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the link below.

Data sharing details ↗ · www.amgen.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2016 to primary completion in Mar 2022, 66 months.

Results were first posted in Feb 2023, 11 months after primary completion.

Of 52 industry-sponsored phase 3 interventional studies under Dyslipidemias, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 36. This study's 66 months is above that.

Counting every sponsor, half of 62 studies reached it within 22 months; a quarter within 12 and three quarters within 45.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 20, 2016
First posted
Aug 16, 2016
StartActual
Sep 2, 2016
Primary completionActual
Mar 21, 2022
CompletionActual
Mar 21, 2022
Results first posted
Feb 28, 2023
Last update
Apr 7, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 7, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02867813
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Aug 16, 2016
Start date
Sep 2, 2016
Primary completion
Mar 21, 2022
Completion
Mar 21, 2022
Results posted
Feb 28, 2023
Last update
Apr 7, 2023

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Evolocumab

Start the discussion